Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob. 2019;18:7.
Syed I, Wooten RM. Interactions between pathogenic Burkholderia and the complement system: a review of potential immune evasion mechanisms. Front Cell Infect Microbiol. 2021;11:701362.
Schaefers MM. Regulation of virulence by two-component systems in pathogenic Burkholderia. Infect Immun. 2020;88:e00927–19.
Hauser N, Orsini J. Cepacia syndrome in a non-cystic fibrosis patient. Case Rep Infect Dis. 2015;2015:1–4.
Lord R, Jones AM, Horsley A. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2020;2020:CD009529.
Li X, Wang K, Wang G, Cui B, Song S, Sun X, Deng Y. Oridonin attenuates Burkholderia cenocepacia virulence by suppressing quorum- sensing signaling. Microbiol Spectr. 2022;10:e0178722.
Silva-Santana G, Sales FLS, Aguiar AR, Brandão MLL. Pharmaceutical contamination by biofilms formed of the Burkholderia cepacia complex: public health risks. Processes. 2025;13:1270.
Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, Mohsen Y, Adukkadukkam S, Awuah WA, Jose RAM, Sylvia N, Nansubuga EP, Tilocca B, Roncada P, Roson-Calero N, Moreno-Morales J, Amin R, Kumar BK, Kumar A, Toufik AR, Zaw TN, Akinwotu OO, Satyaseela MP, van Dongen MBM. Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics. Antibiotics. 2022;11:200.
Zigangirova NA, Lubenec NL, Beloborodov VB, Sheremet AB, Nelyubina SA, Bondareva NE, Zakharov KA, Luyksaar SI, Zolotov SA, Levchenko EU, Luyksaar SV, Koroleva EA, Fedina ED, Simakova YV, Pushkar DY, Gintzburg AL. A new “non-traditional” antibacterial drug fluorothiazinone-clinical research in patients with complicated urinary tract infections. Antibiotics (Basel). 2024;13:476.
Koroleva EA, Kobets NV, Zayakin ES, Luyksaar SI, Shabalina LA, Zigangirova NA. Small-molecule inhibitor of type three secretion suppresses acute and chronic Chlamydia trachomatis infection in a novel urogenital Chlamydia model. BioMed Res. Int. 2015;2015:1–7.
Sheremet AB, Zigangirova NA, Zayakin ES, Luyksaar SI, Kapotina LN, Nesterenko LN, Kobets NV, Gintsburg AL. Small molecule inhibitor of type three secretion system belonging to a class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones improves survival and decreases bacterial loads in an airway Pseudomonas aeruginosa infection in mice. BioMed Res.Int. 2018;2018:1–13.
Bondareva NE, Soloveva AV, Sheremet AB, Koroleva EA, Kapotina LN, Morgunova EY, Luyksaar SI, Zayakin ES, Zigangirova NA. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. J. Antibiot. 2022;75:155–63.
Koroleva EA, Soloveva AV, Morgunova EY, Kapotina LN, Luyksaar SI, Luyksaar SV, Bondareva NE, Nelubina SA, Lubenec NL, Zigangirova NA, Gintsburg AL. Fluorothiazinon inhibits the virulence factors of uropathogenic Escherichia coli involved in the development of urinary tract infection. J. Antibiot. 2023;76:279–90.
Tsarenko SV, Zigangirova NA, Soloveva AV, Bondareva NE, Koroleva EA, Sheremet AB, Kapotina LN, Shevlyagina NV, Andreevskaya SG, Zhukhovitsky VG, Filimonova EV, Gintsburg AL. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. J. Antibiot. 2023;76:397–405.
Savitskii MV, Moskaleva NE, Brito A. Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model. J Pharm Biomed Anal. 2023;236:115739.
Facchini M, De Fino I, Riva C, Bragonzi A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014;85:51019.
Pirone L, Bragonzi A, Farcomeni A, Paroni M, Auriche C, Conese M, Chiarini L, Dalmastri C, Bevivino A, Ascenzioni F. Burkholderia cenocepacia strains isolated from cystic fibrosis patients are apparently more invasive and more virulent than rhizosphere strains. Environ. Microbiol. 2008;10:2773–84.
Bragonzi A, Worlitzsch D, Pier GB, Timpert P, Ulrich M, Hentzer M, Andersen JB, Givskov M, Conese M, Doring G. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis. 2005;192:410–9.
Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med. 2009;180:138–45.
Riedel K, Hentzer M, Geisenberger O, Huber B, Steidle A, Wu H, Høiby N, Givskov M, Molin S, Eberl L. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (Reading). 2001;147:3249–62.
Chu KK, Davidson DJ, Halsey TK, Chung JW, Speert DP. Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun. 2002;70:2715–20.
Perikleous EP, Gkentzi D, Bertzouanis A, Paraskakis E, Sovtic A, Fouzas S. Antibiotic resistance in patients with cystic fibrosis: past, present, and future. Antibiotics. 2023;12:217.
Scoffone VC, Chiarelli LR, Trespidi G, Mentasti M, Riccardi G, Buroni S. Burkholderia cenocepacia infections in cystic fibrosis patients: drug resistance and therapeutic approaches. Front Microbiol. 2017;8:1592.
Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V. Clinafloxacin for treatment of Burkholderia cenocepacia infection in a cystic fibrosis patient. Antimicrob Agents Chemother. 2016;60:1–5.
Chernish RN, Aaron SD. Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med. 2003;9:509–15.
Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2000;161:1206–12.
Tomich M, Griffith A, Herfst CA, Burns JL, Mohr CD. Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection. Infect Immun. 2003;71:1405–15.
Selim H, Radwan TEE, Reyad AM. Regulation of T3SS synthesis, assembly and secretion in Pseudomonas aeruginosa Arch Microbiol. Arch Microbiol. 2022;204:468.
Loutet SA, Valvano MA. A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun. 2010;78:4088–100.
Huynh KK, Plumb JD, Downey GP, Valvano MA, Grinstein S. Inactivation of macrophage Rab7 by Burkholderia cenocepacia. J Innate Immun. 2010;2:522–33.
